Charles Schwab
BTAI icon

Charles Schwab’s BioXcel Therapeutics BTAI Stock Holding History

Charles Schwab’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12,726
Closed -$261K – 3513
2024
Q2 		$261K Buy
12,726
+790
+7% +$26.4K ﹤0.01% 3401
2024
Q1 		$539K Buy
11,936
+217
+2% +$10.4K ﹤0.01% 2997
2023
Q4 		$553K Buy
11,719
+3,169
+37% +$176K ﹤0.01% 3040
2023
Q3 		$346K Sell
8,550
-711
-8% -$71.9K ﹤0.01% 3187
2023
Q2 		$987K Buy
9,261
+268
+3% +$89.2K ﹤0.01% 2773
2023
Q1 		$2.69M Buy
8,993
+38
+0.4% +$16.2K ﹤0.01% 2444
2022
Q4 		$3.08M Buy
8,955
+174
+2% +$42.1K ﹤0.01% 2429
2022
Q3 		$1.66M Buy
8,781
+960
+12% +$223K ﹤0.01% 2631
2022
Q2 		$1.65M Sell
7,821
-636
-8% -$134K ﹤0.01% 2621
2022
Q1 		$2.83M Buy
8,457
+225
+3% +$65.2K ﹤0.01% 2531
2021
Q4 		$2.68M Buy
8,232
+109
+1% +$46.8K ﹤0.01% 2603
2021
Q3 		$3.94M Buy
8,123
+1,701
+26% +$748K ﹤0.01% 2476
2021
Q2 		$2.99M Buy
6,422
+421
+7% +$229K ﹤0.01% 2590
2021
Q1 		$4.14M Buy
6,001
+150
+3% +$121K ﹤0.01% 2382
2020
Q4 		$4.33M Buy
5,851
+171
+3% +$133K ﹤0.01% 2294
2020
Q3 		$3.94M Buy
5,680
+4,029
+244% +$3.03M ﹤0.01% 2193
2020
Q2 		$1.4M Buy
1,651
+699
+73% +$456K ﹤0.01% 2538
2020
Q1 		$341K Buy
952
+9
+1% +$3.23K ﹤0.01% 2838
2019
Q4 		$221K Buy
943
+159
+20% +$16K ﹤0.01% 3025
2019
Q3 		$89K Hold
784
– – ﹤0.01% 3098
2019
Q2 		$138K Buy
+784
New +$133K ﹤0.01% 3115

Other funds holding BTAI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Charles Schwab's BTAI Position: Q3 2024 in Review

Charles Schwab sold out of BioXcel Therapeutics (BTAI) in Q3 2024, closing a stake of 12,726 shares — an estimated $261K sold.

Charles Schwab first reported a position in BTAI in Q2 2019 and held it in 21 quarters. The position peaked at $4.33M in Q4 2020. 49 funds tracked by Wall St. Rank hold BTAI as of Q3 2024.

  • Charles Schwab reported no remaining BioXcel Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Charles Schwab sold 12,726 BioXcel Therapeutics shares in Q3 2024, an estimated $261K.
  • Charles Schwab first reported a position in BioXcel Therapeutics in Q2 2019 and held it in 21 quarters.
  • Charles Schwab's BioXcel Therapeutics position peaked at $4.33M in Q4 2020.
  • 49 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2024.

Based on Charles Schwab's 13F filing for Q3 2024, filed 12 Nov 2024.